Innate Pharma S.A.
OTC: IPHYF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan E. Dickinson
- Employees
- 181
- Headquarters
- Marseille, France
- IPO year
- 2015
- Market cap
- $154.9M
- Website
- https://www.innate-pharma.com
Loading IPHYF…
Loading profile data…Frequently asked questions about IPHYF
What does Innate Pharma S.A. (IPHYF) do?
Innate Pharma S.A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3D...
Where does IPHYF trade?
Innate Pharma S.A. (IPHYF) trades on the Other OTC.
What sector is IPHYF in?
Innate Pharma S.A. (IPHYF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Innate Pharma S.A.?
Jonathan E. Dickinson is the chief executive officer of Innate Pharma S.A. (IPHYF).
Where is Innate Pharma S.A. headquartered?
Innate Pharma S.A. is headquartered in France.
Does IPHYF pay a dividend?
Innate Pharma S.A. (IPHYF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IPHYF go public?
Innate Pharma S.A. (IPHYF) completed its initial public offering in 2015.